Cargando…
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent y...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554687/ https://www.ncbi.nlm.nih.gov/pubmed/36248331 http://dx.doi.org/10.21037/tlcr-22-629 |
_version_ | 1784806756565647360 |
---|---|
author | Wang, Yadong Peng, Ling Zhao, Ming Xiong, Yuanyuan Xue, Jianchao Li, Bowen Huang, Zhicheng Liu, Xinyu Yang, Xiaoying Song, Yang Bing, Zhongxing Guo, Chao Tian, Zhenhuan Gao, Chao Cao, Lei Cao, Zhili Li, Ji Jiang, Xu Si, Xiaoyan Zhang, Li Li, Xiaoguang Zheng, Zhibo Song, Mengmeng Chen, Rongrong Lim, Wan-Teck Pavan, Alberto Romero, Atocha Liang, Naixin Yang, Huaxia Li, Shanqing |
author_facet | Wang, Yadong Peng, Ling Zhao, Ming Xiong, Yuanyuan Xue, Jianchao Li, Bowen Huang, Zhicheng Liu, Xinyu Yang, Xiaoying Song, Yang Bing, Zhongxing Guo, Chao Tian, Zhenhuan Gao, Chao Cao, Lei Cao, Zhili Li, Ji Jiang, Xu Si, Xiaoyan Zhang, Li Li, Xiaoguang Zheng, Zhibo Song, Mengmeng Chen, Rongrong Lim, Wan-Teck Pavan, Alberto Romero, Atocha Liang, Naixin Yang, Huaxia Li, Shanqing |
author_sort | Wang, Yadong |
collection | PubMed |
description | BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent years. However, the efficacy of immunotherapy in KRAS mutant NSCLC is variable. Analysis of T cell receptor (TCR) repertoire may contribute to a better understanding of the mechanisms behind such differential outcomes. METHODS: A total of 47 patients with KRAS mutant NSCLC were enrolled in this study. Deep sequencing of the TCR β chain complementarity-determining regions in tumor tissue and paired peripheral blood specimens was conducted. Comprehensive analysis of TCR repertoire metrics was performed with different KRAS mutation subtypes and concomitant mutations. Moreover, the associations between TCR repertoire metrics and tumor mutation burden (TMB), as well as programmed death-ligand 1 were explored, respectively. RESULTS: TCR repertoire metrics, including Shannon index, Clonality, and Morisita index (MOI), showed no significant differences among different KRAS mutation subtypes. The similar results were observed between patients with tumor protein p53 (TP53) mutation and those with wild-type TP53. In contrast, although no significant differences were found in Shannon index and Clonality, patients with KRAS/serine/threonine kinase 11 (STK11) comutation showed a significantly higher MOI compared to their STK11 wild-type counterparts (P=0.012). In addition, TCR repertoire metrics were neither associated with TMB nor programmed death-ligand 1 expression in KRAS mutant NSCLC. CONCLUSIONS: This retrospective study comprehensively described the TCR repertoire in KRAS mutant NSCLC. A higher MOI represented more overlap of the TCR repertoire between tumor tissue and paired peripheral blood, indicating distinctive immunological features in NSCLC with KRAS/STK11 comutation. |
format | Online Article Text |
id | pubmed-9554687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-95546872022-10-13 Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer Wang, Yadong Peng, Ling Zhao, Ming Xiong, Yuanyuan Xue, Jianchao Li, Bowen Huang, Zhicheng Liu, Xinyu Yang, Xiaoying Song, Yang Bing, Zhongxing Guo, Chao Tian, Zhenhuan Gao, Chao Cao, Lei Cao, Zhili Li, Ji Jiang, Xu Si, Xiaoyan Zhang, Li Li, Xiaoguang Zheng, Zhibo Song, Mengmeng Chen, Rongrong Lim, Wan-Teck Pavan, Alberto Romero, Atocha Liang, Naixin Yang, Huaxia Li, Shanqing Transl Lung Cancer Res Original Article BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC). The administration of immunotherapy has demonstrated significant efficacy in prolonging the overall survival of patients with KRAS mutation in recent years. However, the efficacy of immunotherapy in KRAS mutant NSCLC is variable. Analysis of T cell receptor (TCR) repertoire may contribute to a better understanding of the mechanisms behind such differential outcomes. METHODS: A total of 47 patients with KRAS mutant NSCLC were enrolled in this study. Deep sequencing of the TCR β chain complementarity-determining regions in tumor tissue and paired peripheral blood specimens was conducted. Comprehensive analysis of TCR repertoire metrics was performed with different KRAS mutation subtypes and concomitant mutations. Moreover, the associations between TCR repertoire metrics and tumor mutation burden (TMB), as well as programmed death-ligand 1 were explored, respectively. RESULTS: TCR repertoire metrics, including Shannon index, Clonality, and Morisita index (MOI), showed no significant differences among different KRAS mutation subtypes. The similar results were observed between patients with tumor protein p53 (TP53) mutation and those with wild-type TP53. In contrast, although no significant differences were found in Shannon index and Clonality, patients with KRAS/serine/threonine kinase 11 (STK11) comutation showed a significantly higher MOI compared to their STK11 wild-type counterparts (P=0.012). In addition, TCR repertoire metrics were neither associated with TMB nor programmed death-ligand 1 expression in KRAS mutant NSCLC. CONCLUSIONS: This retrospective study comprehensively described the TCR repertoire in KRAS mutant NSCLC. A higher MOI represented more overlap of the TCR repertoire between tumor tissue and paired peripheral blood, indicating distinctive immunological features in NSCLC with KRAS/STK11 comutation. AME Publishing Company 2022-09 /pmc/articles/PMC9554687/ /pubmed/36248331 http://dx.doi.org/10.21037/tlcr-22-629 Text en 2022 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wang, Yadong Peng, Ling Zhao, Ming Xiong, Yuanyuan Xue, Jianchao Li, Bowen Huang, Zhicheng Liu, Xinyu Yang, Xiaoying Song, Yang Bing, Zhongxing Guo, Chao Tian, Zhenhuan Gao, Chao Cao, Lei Cao, Zhili Li, Ji Jiang, Xu Si, Xiaoyan Zhang, Li Li, Xiaoguang Zheng, Zhibo Song, Mengmeng Chen, Rongrong Lim, Wan-Teck Pavan, Alberto Romero, Atocha Liang, Naixin Yang, Huaxia Li, Shanqing Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title_full | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title_fullStr | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title_full_unstemmed | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title_short | Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer |
title_sort | comprehensive analysis of t cell receptor repertoire in patients with kras mutant non-small cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554687/ https://www.ncbi.nlm.nih.gov/pubmed/36248331 http://dx.doi.org/10.21037/tlcr-22-629 |
work_keys_str_mv | AT wangyadong comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT pengling comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT zhaoming comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT xiongyuanyuan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT xuejianchao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT libowen comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT huangzhicheng comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT liuxinyu comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT yangxiaoying comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT songyang comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT bingzhongxing comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT guochao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT tianzhenhuan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT gaochao comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT caolei comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT caozhili comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT liji comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT jiangxu comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT sixiaoyan comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT zhangli comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT lixiaoguang comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT zhengzhibo comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT songmengmeng comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT chenrongrong comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT limwanteck comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT pavanalberto comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT romeroatocha comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT liangnaixin comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT yanghuaxia comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer AT lishanqing comprehensiveanalysisoftcellreceptorrepertoireinpatientswithkrasmutantnonsmallcelllungcancer |